Dr. Erika Maestas
Claim this profileUniversity of New Mexico Cancer Center
Area of expertise
Pancreatic Cancer
Erika Maestas has run 1 trial for Pancreatic Cancer. Some of their research focus areas include:
Pancreatic Carcinoma
Erika Maestas has run 1 trial for Pancreatic Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
University Of New Mexico Cancer Center
Clinical Trials Erika Maestas is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) with or without nivolumab for the treatment of patients with advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, or gastric adenocarcinoma. The usual approach for patients who are not in a study is treatment with FOLFOX with some receiving an immunotherapy drug, either nivolumab or pembrolizumab, in addition to FOLFOX chemotherapy. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction. Fluorouracil is in a class of medications called antimetabolites. It stops cells from making DNA and may kill tumor cells. Leucovorin in a class of medications called folic acid analogs. When used with fluorouracil it enhances the effects of this chemotherapy drug. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair, and may kill cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Some patients on this trial will receive nivolumab, in addition to mFOLFOX or mFOLFIRINOX chemotherapy. mFOLFIRINOX with or without nivolumab may be more effective than mFOLFOX with or without nivolumab by shrinking the tumor in patients with advanced, unresectable, or metastatic HER2-negative esophageal, gastroesophageal junction, or gastric adenocarcinoma.
Recruiting
2 awards
Phase 3
2 criteria
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting
0 awards
Phase 2
32 criteria
More about Erika Maestas
Clinical Trial Related
3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Erika Maestas has experience with
- Olaparib
- Cisplatin
- Radiation Therapy
- MFOLFIRINOX
- MFOLFOX
- Nivolumab
Breakdown of trials Erika Maestas has run
Pancreatic Cancer
Pancreatic Carcinoma
Oropharyngeal Carcinoma
Fallopian Tube Carcinoma
Oropharyngeal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Erika Maestas specialize in?
Erika Maestas focuses on Pancreatic Cancer and Pancreatic Carcinoma. In particular, much of their work with Pancreatic Cancer has involved BRCA1 positive patients, or patients who are BRCA2 positive.
Is Erika Maestas currently recruiting for clinical trials?
Yes, Erika Maestas is currently recruiting for 2 clinical trials in Albuquerque New Mexico. If you're interested in participating, you should apply.
Are there any treatments that Erika Maestas has studied deeply?
Yes, Erika Maestas has studied treatments such as Olaparib, Cisplatin, Radiation Therapy.
What is the best way to schedule an appointment with Erika Maestas?
Apply for one of the trials that Erika Maestas is conducting.
What is the office address of Erika Maestas?
The office of Erika Maestas is located at: University of New Mexico Cancer Center, Albuquerque, New Mexico 87106 United States. This is the address for their practice at the University of New Mexico Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.